# TG Therapeutics, Inc.: financial statements, quarterly

TGTX · Nasdaq · CIK 1001316 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tgtx.md) · [Financials](/companies/tgtx/financials.md) · [Filings](/companies/tgtx/filings.md) · [Insiders](/companies/tgtx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tgtx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [166](/filings/0001437749-24-033948.md) | [44.0 d](/filings/0001437749-26-006133.md) | [63.5](/filings/0001437749-25-015804.md) | [73.5](/filings/0001437749-25-025745.md) | [83.9](/filings/0001437749-25-033363.md) | [108 d](/filings/0001437749-26-006133.md) | [121](/filings/0001437749-26-015246.md) | [141](/filings/0001437749-26-025955.md) | [162](/filings/0001437749-25-033363.md) | [193 d](/filings/0001437749-26-006133.md) | [205](/filings/0001437749-26-015246.md) | [240](/filings/0001437749-26-025955.md) |
| Cost of revenue | $m | [3.5](/filings/0001437749-24-033948.md) | [7.9 d](/filings/0001437749-26-006133.md) | [5.4](/filings/0001437749-25-015804.md) | [8.3](/filings/0001437749-25-025745.md) | [9.3](/filings/0001437749-25-033363.md) | [15.4 d](/filings/0001437749-26-006133.md) | [15.5](/filings/0001437749-26-015246.md) | [18.9](/filings/0001437749-26-025955.md) | [28.1](/filings/0001437749-25-033363.md) | [38.1 d](/filings/0001437749-26-006133.md) | [33.5](/filings/0001437749-26-015246.md) | [41.2](/filings/0001437749-26-025955.md) |
| Research and development | $m | [14.8](/filings/0001437749-24-033948.md) | [17.4 d](/filings/0001437749-26-006133.md) | [32.7](/filings/0001437749-25-015804.md) | [17.6](/filings/0001437749-25-025745.md) | [20.1](/filings/0001437749-25-033363.md) | [23.9 d](/filings/0001437749-26-006133.md) | [46.4](/filings/0001437749-26-015246.md) | [31.8](/filings/0001437749-26-025955.md) | [40.9](/filings/0001437749-25-033363.md) | [41.2 d](/filings/0001437749-26-006133.md) | [48.4](/filings/0001437749-26-015246.md) | [95.3](/filings/0001437749-26-025955.md) |
| Selling, general and administrative | $m | [32.8](/filings/0001437749-24-033948.md) | [31.2 d](/filings/0001437749-26-006133.md) | [34.6](/filings/0001437749-25-015804.md) | [38.8](/filings/0001437749-25-025745.md) | [42.0](/filings/0001437749-25-033363.md) | [39.0 d](/filings/0001437749-26-006133.md) | [50.3](/filings/0001437749-26-015246.md) | [55.6](/filings/0001437749-26-025955.md) | [63.4](/filings/0001437749-25-033363.md) | [62.7 d](/filings/0001437749-26-006133.md) | [88.2](/filings/0001437749-26-015246.md) | [82.1](/filings/0001437749-26-025955.md) |
| Operating income | $m | [115](/filings/0001437749-24-033948.md) | [(12.5) d](/filings/0001437749-26-006133.md) | [(9.3)](/filings/0001437749-25-015804.md) | [8.8](/filings/0001437749-25-025745.md) | [12.4](/filings/0001437749-25-033363.md) | [29.9 d](/filings/0001437749-26-006133.md) | [8.6](/filings/0001437749-26-015246.md) | [34.8](/filings/0001437749-26-025955.md) | [29.4](/filings/0001437749-25-033363.md) | [50.5 d](/filings/0001437749-26-006133.md) | [34.8](/filings/0001437749-26-015246.md) | [21.7](/filings/0001437749-26-025955.md) |
| Interest expense | $m | [3.7](/filings/0001437749-23-030412.md) | [2.4 d](/filings/0001437749-24-006144.md) | [2.3](/filings/0001437749-24-014849.md) | [4.0](/filings/0001437749-25-025745.md) | [10.8](/filings/0001437749-25-033363.md) | [7.1 d](/filings/0001437749-26-006133.md) | [6.8](/filings/0001437749-26-015246.md) | [6.7](/filings/0001437749-26-025955.md) | [6.7](/filings/0001437749-25-033363.md) | [6.5 d](/filings/0001437749-26-006133.md) | [7.7](/filings/0001437749-26-015246.md) | [16.6](/filings/0001437749-26-025955.md) |
| Income tax | $m | [0.0](/filings/0001437749-24-033948.md) | [0.4 d](/filings/0001437749-26-006133.md) | [0.0](/filings/0001437749-25-015804.md) | [(0.3)](/filings/0001437749-25-025745.md) | [0.4](/filings/0001437749-25-033363.md) | [2.1 d](/filings/0001437749-26-006133.md) | [0.4](/filings/0001437749-26-015246.md) | [2.7](/filings/0001437749-26-025955.md) | [(365)](/filings/0001437749-25-033363.md) | [22.1 d](/filings/0001437749-26-006133.md) | [0.6](/filings/0001437749-26-015246.md) | [2.5](/filings/0001437749-26-025955.md) |
| Net income | $m | [114](/filings/0001437749-24-033948.md) | [(14.4) d](/filings/0001437749-26-006133.md) | [(10.7)](/filings/0001437749-25-033363.md) | [6.9](/filings/0001437749-25-033363.md) | [3.9](/filings/0001437749-25-033363.md) | [23.3 d](/filings/0001437749-26-006133.md) | [5.1](/filings/0001437749-26-025955.md) | [28.2](/filings/0001437749-26-025955.md) | [391](/filings/0001437749-25-033363.md) | [23.0 d](/filings/0001437749-26-006133.md) | [19.8](/filings/0001437749-26-025955.md) | [7.8](/filings/0001437749-26-025955.md) |
| Diluted EPS | $ per share | [0.73](/filings/0001437749-24-033948.md) | not reported | [(0.07)](/filings/0001437749-25-015804.md) | [0.04](/filings/0001437749-25-025745.md) | [0.02](/filings/0001437749-25-033363.md) | not reported | [0.03](/filings/0001437749-26-015246.md) | [0.17](/filings/0001437749-26-025955.md) | [2.43](/filings/0001437749-25-033363.md) | not reported | [0.12](/filings/0001437749-26-015246.md) | [0.05](/filings/0001437749-26-025955.md) |
| Basic EPS | $ per share | [0.80](/filings/0001437749-24-033948.md) | not reported | [(0.07)](/filings/0001437749-25-015804.md) | [0.05](/filings/0001437749-25-025745.md) | [0.03](/filings/0001437749-25-033363.md) | not reported | [0.03](/filings/0001437749-26-015246.md) | [0.19](/filings/0001437749-26-025955.md) | [2.69](/filings/0001437749-25-033363.md) | not reported | [0.14](/filings/0001437749-26-015246.md) | [0.05](/filings/0001437749-26-025955.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [151](/filings/0001437749-24-033948.md) | [92.9](/filings/0001437749-26-006133.md) | [75.5](/filings/0001437749-25-015804.md) | [82.9](/filings/0001437749-25-025745.md) | [196](/filings/0001437749-25-033363.md) | [180](/filings/0001437749-26-006133.md) | [132](/filings/0001437749-26-015246.md) | [129](/filings/0001437749-26-025955.md) | [74.1](/filings/0001437749-25-033363.md) | [79.1](/filings/0001437749-26-025955.md) | [442](/filings/0001437749-26-015246.md) | [483](/filings/0001437749-26-025955.md) |
| Current assets | $m | [319](/filings/0001437749-23-030412.md) | [318](/filings/0001437749-25-005908.md) | [361](/filings/0001437749-24-014849.md) | [389](/filings/0001437749-24-025853.md) | [574](/filings/0001437749-24-033948.md) | [566](/filings/0001437749-26-006133.md) | [645](/filings/0001437749-25-015804.md) | [664](/filings/0001437749-25-025745.md) | [600](/filings/0001437749-25-033363.md) | [631](/filings/0001437749-26-025955.md) | [1,087](/filings/0001437749-26-015246.md) | [1,146](/filings/0001437749-26-025955.md) |
| Total assets | $m | [331](/filings/0001437749-23-030412.md) | [330](/filings/0001437749-25-005908.md) | [373](/filings/0001437749-24-014849.md) | [401](/filings/0001437749-24-025853.md) | [586](/filings/0001437749-24-033948.md) | [578](/filings/0001437749-26-006133.md) | [657](/filings/0001437749-25-015804.md) | [703](/filings/0001437749-25-025745.md) | [1,025](/filings/0001437749-25-033363.md) | [1,063](/filings/0001437749-26-025955.md) | [1,529](/filings/0001437749-26-015246.md) | [1,640](/filings/0001437749-26-025955.md) |
| Current liabilities | $m | [57.7](/filings/0001437749-23-030412.md) | [53.7](/filings/0001437749-25-005908.md) | [99.7](/filings/0001437749-24-014849.md) | [109](/filings/0001437749-24-025853.md) | [125](/filings/0001437749-24-033948.md) | [90.7](/filings/0001437749-26-006133.md) | [160](/filings/0001437749-25-015804.md) | [172](/filings/0001437749-25-025745.md) | [157](/filings/0001437749-25-033363.md) | [154](/filings/0001437749-26-025955.md) | [187](/filings/0001437749-26-015246.md) | [268](/filings/0001437749-26-025955.md) |
| Total liabilities | $m | [166](/filings/0001437749-23-030412.md) | [169](/filings/0001437749-25-005908.md) | [213](/filings/0001437749-24-014849.md) | [224](/filings/0001437749-24-025853.md) | [394](/filings/0001437749-24-033948.md) | [355](/filings/0001437749-26-006133.md) | [419](/filings/0001437749-25-015804.md) | [426](/filings/0001437749-25-025745.md) | [418](/filings/0001437749-25-033363.md) | [415](/filings/0001437749-26-025955.md) | [946](/filings/0001437749-26-015246.md) | [1,036](/filings/0001437749-26-025955.md) |
| Long-term debt | $m | [98.9](/filings/0001437749-23-030412.md) | [100](/filings/0001437749-25-005908.md) | [101](/filings/0001437749-24-014849.md) | [103](/filings/0001437749-24-025853.md) | [244](/filings/0001437749-24-033948.md) | [244](/filings/0001437749-26-006133.md) | [245](/filings/0001437749-25-015804.md) | [245](/filings/0001437749-25-025745.md) | [245](/filings/0001437749-25-033363.md) | [246](/filings/0001437749-26-025955.md) | [745](/filings/0001437749-26-015246.md) | [745](/filings/0001437749-26-025955.md) |
| Current portion of debt | $m | [0.0](/filings/0001437749-23-030412.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [165](/filings/0001437749-24-033948.md) | [161](/filings/0001437749-26-006133.md) | [160](/filings/0001437749-25-033363.md) | [178](/filings/0001437749-25-033363.md) | [192](/filings/0001437749-25-033363.md) | [222](/filings/0001437749-26-025955.md) | [237](/filings/0001437749-26-025955.md) | [276](/filings/0001437749-26-025955.md) | [607](/filings/0001437749-25-033363.md) | [648](/filings/0001437749-26-025955.md) | [583](/filings/0001437749-26-025955.md) | [604](/filings/0001437749-26-025955.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [83.7 d](/filings/0001437749-24-033948.md) | [(13.2) d](/filings/0001437749-26-006133.md) | [(8.2)](/filings/0001437749-25-015804.md) | [5.5 d](/filings/0001437749-25-025745.md) | [(12.2) d](/filings/0001437749-25-033363.md) | [(25.6) d](/filings/0001437749-26-006133.md) | [(28.7)](/filings/0001437749-26-015246.md) | [7.4 d](/filings/0001437749-26-025955.md) | [(23.2) d](/filings/0001437749-25-033363.md) | [19.7 d](/filings/0001437749-26-006133.md) | [(17.9)](/filings/0001437749-26-015246.md) | [39.3 d](/filings/0001437749-26-025955.md) |
| Capital expenditure | $m | not reported | [0.0 d](/filings/0001437749-26-006133.md) | [0.0](/filings/0001437749-25-015804.md) | [0.0 d](/filings/0001437749-25-025745.md) | [0.0 d](/filings/0001437749-25-033363.md) | [0.0 d](/filings/0001437749-26-006133.md) | [0.0](/filings/0001437749-26-015246.md) | [0.0 d](/filings/0001437749-26-025955.md) | [0.1 d](/filings/0001437749-25-033363.md) | [0.1 d](/filings/0001437749-26-006133.md) | [0.1](/filings/0001437749-26-015246.md) | [0.3 d](/filings/0001437749-26-025955.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [135](/filings/0001437749-23-030412.md) | [140](/filings/0001558370-23-008385.md) | [142](/filings/0001437749-24-025853.md) | [156](/filings/0001437749-24-033948.md) | [146](/filings/0001437749-25-015804.md) | [159](/filings/0001437749-25-025745.md) | [161](/filings/0001437749-25-033363.md) | [163](/filings/0001437749-26-015246.md) | [163](/filings/0001437749-26-025955.md) | [161](/filings/0001437749-25-033363.md) | [160](/filings/0001437749-26-015246.md) | [157](/filings/0001437749-26-025955.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 153,069,053 at 2026-08-03, from the cover of the [10-Q filed 2026-08-05](/filings/0001437749-26-025955.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.